Bio-IT World August 2, 2024
Allison Proffitt

BioTeam announced its acquisition today by British firm n2 Group. BioTeam will be a US-based, independent business within n2 Group. Financial details have not been disclosed.

“This was a unicorn deal,” Stan Gloss, BioTeam co-founder and fellow told Bio-IT World. “BioTeam can stay BioTeam and now we’re in the position to fund good academic research that advances science in our field.”

Ari Berman, BioTeam’s CEO, agreed. “BioTeam is a pretty unique company in a lot of good ways, and we’ve had a lot of opportunities for acquisition over the years, but [co-founders] Stan [Gloss] and Chris [Dagdigian] really held off in hopes that we might find somebody who would want to buy us because they like who we are...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Related Articles:
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA

Share This Article